NCT04416646 (ZEBRA) is a clinical trial of Cabozantinib in Renal Cell Carcinoma, sponsored by Istituto Oncologico Veneto IRCCS.

Who is sponsoring NCT04416646?

NCT04416646 is sponsored by Istituto Oncologico Veneto IRCCS.

What drugs are being tested in NCT04416646?

Interventions in NCT04416646: Cabozantinib.

What condition does NCT04416646 study?

NCT04416646 studies Renal Cell Carcinoma.

Is NCT04416646 still recruiting?

NCT04416646 is currently completed. Last updated 13 April 2026.

Last reviewed 2026-04-13 · How we verify

NCT04416646: ZEBRA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cabozantinib in the Elderly With Metastatic Renal Cell Carcinoma

Completed Last updated 13 April 2026

What this trial tests

trial testing Cabozantinib in Renal Cell Carcinoma in 100 participants. Completed in 31 December 2023.

Timeline

27 February 2019

Primary endpoint
26 June 2023

31 December 2023

Quick facts

Lead sponsor	Istituto Oncologico Veneto IRCCS
Status	Completed
Study type	OBSERVATIONAL
Enrollment	100
Start date	27 February 2019
Primary completion	26 June 2023
Estimated completion	31 December 2023
Sites	1 location across Italy

Drugs / interventions tested

Cabozantinib (CABOZANTINIB) — full drug profile →

Conditions studied

Renal Cell Carcinoma — all drugs for Renal Cell Carcinoma →

Sponsor

Istituto Oncologico Veneto IRCCS — full company profile →

Who can join

70 and older, any sex, with Renal Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety and efficacy of Cabozantinib in the treatment of patients with renal cell carcinoma.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

BDNF and its signaling in cancer.
Malekan M, Nezamabadi SS, Samami E, Mohebalizadeh M, et al · · 2023 · cited 48× · PMID 36173463 · DOI 10.1007/s00432-022-04365-8

Verify or expand the search:

Other trials of Cabozantinib

Trials testing the same drug.

NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting
NCT07293351 — A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Caboz · Phase 1, PHASE2 · recruiting
NCT07187869 — Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell · Phase 1 · not yet recruiting
NCT07405164 — Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) · Phase 3 · recruiting
NCT06900595 — Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescent · Phase 2 · recruiting

Other recruiting trials for Renal Cell Carcinoma

Currently open trials in the same condition.

NCT07397611 — Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC · Phase 2 · recruiting
NCT07195682 — A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) · Phase 1 · recruiting
NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
NCT07227402 — A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6 · Phase 3 · recruiting
NCT07123090 — A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma · Phase 2 · recruiting

Other Istituto Oncologico Veneto IRCCS trials

Trials by the same sponsor.

NCT07185568 — IntraOperative UltraSound Guided vs Wire Guided vs Magnetic Seed Guided Breast-Conserving Surgery for Non-palpable Tumor · NA · not yet recruiting
NCT07338292 — VIrtual Reality Induced Pain and anxiEty Relief in Outpatient UROlogical Procedures · NA · recruiting
NCT06753136 — Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histo · NA · recruiting
NCT06595498 — Next Generation Sequencing Method for the Detection of EGFR Gene Mutations in the Plasma of Patients With Lung Cancer · NA · active not recruiting
NCT06600568 — Novel Therapeutic Approach for Human T-cell Malignancies · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04416646 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Istituto Oncologico Veneto IRCCS
Last refreshed: 13 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04416646.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing